<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Digital Diagnostics</journal-id><journal-title-group><journal-title xml:lang="en">Digital Diagnostics</journal-title><trans-title-group xml:lang="ru"><trans-title>Digital Diagnostics</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Digital Diagnostics</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2712-8490</issn><issn publication-format="electronic">2712-8962</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">623183</article-id><article-id pub-id-type="doi">10.17816/DD623183</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Reviews</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Научные обзоры</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="zh"><subject>科学评论</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Multiparametric magnetic resonance imaging and magnetic resonance imaging fusion-guided biopsy for the diagnosis of prostate cancer: current status</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности мультипараметрической магнитно-резонансной томографии при проведении фьюжн-биопсии под её контролем в диагностике рака предстательной железы: текущий статус</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>融合引导活检在前列腺癌诊断中的多参数磁共振成像功能：现状</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1231-5213</contrib-id><name><surname>Testini</surname><given-names>Valentina</given-names></name><address><country country="IT">Italy</country></address><bio><p>MD</p></bio><email>testinivalentina@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4172-5126</contrib-id><name-alternatives><name xml:lang="en"><surname>Eusebi</surname><given-names>Laura</given-names></name><name xml:lang="ru"><surname>Eusebi</surname><given-names>Laura</given-names></name><name xml:lang="zh"><surname>Eusebi</surname><given-names>Laura</given-names></name></name-alternatives><address><country country="IT">Italy</country></address><bio><p>MD</p></bio><email>lauraeu@virgilio.it</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3923-3429</contrib-id><name><surname>Guerra</surname><given-names>Francesco Saverio</given-names></name><address><country country="IT">Italy</country></address><bio><p>MD</p></bio><email>francesco.rino@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Giannubilo</surname><given-names>Willy</given-names></name><name xml:lang="ru"><surname>Giannubilo</surname><given-names>Willy</given-names></name><name xml:lang="zh"><surname>Giannubilo</surname><given-names>Willy</given-names></name></name-alternatives><address><country country="IT">Italy</country></address><bio><p>MD</p></bio><email>willygiannubilo@virgilio.it</email><xref ref-type="aff" rid="aff4"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Di Biase</surname><given-names>Manuel</given-names></name><name xml:lang="ru"><surname>Di Biase</surname><given-names>Manuel</given-names></name><name xml:lang="zh"><surname>Di Biase</surname><given-names>Manuel</given-names></name></name-alternatives><address><country country="IT">Italy</country></address><bio><p>MD</p></bio><email>manuel.dibiase@ospedale.perugia.it</email><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Russo</surname><given-names>Annunziata</given-names></name><name xml:lang="ru"><surname>Russo</surname><given-names>Annunziata</given-names></name><name xml:lang="zh"><surname>Russo</surname><given-names>Annunziata</given-names></name></name-alternatives><address><country country="IT">Italy</country></address><bio><p>MD</p></bio><email>tittyrusso-23@libero.it</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4325-8330</contrib-id><name><surname>Guglielmi</surname><given-names>Giuseppe</given-names></name><address><country country="IT">Italy</country></address><bio><p>MD, Professor</p></bio><email>giuseppe.guglielmi@unifg.it</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Foggia University</institution></aff><aff><institution xml:lang="ru">Университет Фоджи</institution></aff><aff><institution xml:lang="zh">Foggia University</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Monsignor Raffaele Dimiccoli</institution></aff><aff><institution xml:lang="ru">Monsignor Raffaele Dimiccoli Hospital</institution></aff><aff><institution xml:lang="zh">Monsignor Raffaele Dimiccoli</institution></aff></aff-alternatives><aff id="aff3"><institution>Carlo Urbani Hospital</institution></aff><aff id="aff4"><institution>Ospedale Civile</institution></aff><aff id="aff5"><institution>Santa Maria della Misericordia Hospital</institution></aff><aff id="aff6"><institution>Casa Sollievo della Sofferenza Hospital</institution></aff><pub-date date-type="preprint" iso-8601-date="2024-07-05" publication-format="electronic"><day>05</day><month>07</month><year>2024</year></pub-date><pub-date date-type="pub" iso-8601-date="2024-09-20" publication-format="electronic"><day>20</day><month>09</month><year>2024</year></pub-date><volume>5</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>283</fpage><lpage>302</lpage><history><date date-type="received" iso-8601-date="2023-11-10"><day>10</day><month>11</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-12-27"><day>27</day><month>12</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-вектор</copyright-holder><copyright-holder xml:lang="zh">Eco-Vector</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://jdigitaldiagnostics.com/DD/article/view/623183">https://jdigitaldiagnostics.com/DD/article/view/623183</self-uri><abstract xml:lang="en"><p>This review explains the role of multiparametric magnetic resonance imaging, particularly in prostate biopsy, in the detection of prostate cancer. The use of multiparametric magnetic resonance imaging in the diagnosis of prostate cancer has also allowed its use in magnetic resonance imaging-guided biopsies, which according to many studies present high sensitivity and specificity in early diagnosis and staging, in patients with persistently high prostate-specific antigen levels despite previous negative prostate biopsies, and in the follow-up of patients under active surveillance.</p> <p>To perform a targeted prostate biopsy, three types of magnetic resonance imaging guidance are available: cognitive fusion, direct magnetic resonance imaging-guided biopsy performed within a tomograph (in-bore biopsies), and software coregistration of stored magnetic resonance images with real-time ultrasound using a fusion device, with multiparametric magnetic resonance imaging findings digitally overlaid on real-time transrectal ultrasound images for targeted biopsy.</p> <p>Each method has its advantages and disadvantages. Magnetic resonance imaging-targeted biopsy improves the quality of histological results compared with other approaches, with approximately 90% correct detection of significant index lesions. Correct staging allows the selection of the best therapeutic options, adequate evaluation of the prognosis, and reduction of the incidence of new biopsies and complications. The current objective is to make magnetic resonance imaging-guided biopsy increasingly available and standardize the technique to minimize inter-operator variability depending on the available system.</p></abstract><trans-abstract xml:lang="ru"><p>В данном обзоре освещается роль мультипараметрической магнитно-резонансной томографии в выявлении рака предстательной железы, в частности — при биопсии простаты. Использование мультипараметрической магнитно-резонансной томографии в диагностике рака простаты позволяет также применять её для биопсии. Мультипараметрическая магнитно-резонансная томография, по данным многих исследований, обладает высокой чувствительностью и специфичностью в ранней диагностике и стадировании у пациентов с сохраняющимся высоким уровнем простатспецифического антигена, несмотря на предыдущие отрицательные биопсии простаты, а также при ведении пациентов, находящихся под активным наблюдением.</p> <p>Для проведения прицельной биопсии простаты существует три типа наведения: когнитивная фьюжн-биопсия; прямая биопсия, направляемая магнитно-резонансной томографией и выполняемая внутри томографа (in-bore); программная корегистрация снимков предоперационной магнитно-резонансной томографии с интраоперационным ультразвуковым исследованием с помощью фьюжн-устройства. При этом при проведении прицельной биопсии результаты мультипараметрической магнитно-резонансной томографии накладываются в цифровом виде на изображения трансректального ультразвукового исследования в реальном времени.</p> <p>Каждый метод имеет свои преимущества и недостатки. Прицельная биопсия с помощью магнитно-резонансной томографии улучшает качество гистологических результатов по сравнению с другими подходами, выявляя значимые индексные поражения с точностью до 90%. Правильное стадирование позволяет выбрать оптимальные варианты лечения, адекватно оценить прогноз, снизить частоту новых биопсий и осложнений. В настоящее время главная задача состоит в том, чтобы сделать биопсию в сочетании с магнитно-резонансной томографией более доступной и стандартизировать технику проведения процедуры, что позволит минимизировать межоператорскую вариабельность в зависимости от используемой системы.</p></trans-abstract><trans-abstract xml:lang="zh"><p>本综述强调了多参数磁共振成像在前列腺癌检测中的作用，特别是在前列腺活检中的作用。多参数磁共振成像技术在前列腺癌诊断中的应用也可用于活检。许多研究报告称，多参数磁共振成像在前列腺活检阴性但前列腺特异性抗原水平持续偏高的患者的早期诊断和分期方面具有很高的灵敏度和特异性，在主动监测患者的管理方面也是如此。</p> <p>前列腺靶向活检有三种引导方式：认知融合引导活检；由磁共振成像引导并在计算机断层扫描仪内（in-bore）进行的直接活检；以及使用融合设备对术前磁共振成像图像和术中超声检查进行的软件联合注册。在这种靶向活检中，多参数磁共振成像结果以数字方式叠加在实时经直肠超声图像上。</p> <p>每种方法都有其优缺点。与其他方法相比，利用磁共振成像进行靶向活检可提高组织学结果的质量，检测重要指标病变的准确率高达 90%。正确的分期可以选择最佳治疗方案，充分评估预后，减少新的活检和并发症的发生。目前的主要任务是使活检与磁共振成像相结合的应用更加广泛，并使手术技术标准化，以最大限度地减少因所使用的系统不同而造成的操作者之间的差异。</p></trans-abstract><kwd-group xml:lang="en"><kwd>multiparametric magnetic resonance imaging</kwd><kwd>prostate cancer</kwd><kwd>fusion biopsy</kwd><kwd>targeted biopsy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мультипараметрическая магнитно-резонансная томография</kwd><kwd>рак предстательной железы</kwd><kwd>фьюжн-биопсия</kwd><kwd>прицельная биопсия</kwd></kwd-group><kwd-group xml:lang="zh"><kwd>多参数磁共振成像</kwd><kwd>前列腺癌</kwd><kwd>融合引导活检</kwd><kwd>靶向活检</kwd></kwd-group><funding-group><funding-statement xml:lang="en">None</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–629. doi: 10.1016/j.eururo.2016.08.003</mixed-citation><mixed-citation xml:lang="ru">Mottet N., Bellmunt J., Bolla M., et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent // Eur Urol. 2017. Vol. 71, N 4. P. 618–629. doi: 10.1016/j.eururo.2016.08.003</mixed-citation><mixed-citation xml:lang="zh">Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017;71(4):618–629. doi: 10.1016/j.eururo.2016.08.003</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713–719. doi: 10.1016/j.eururo.2013.05.059</mixed-citation><mixed-citation xml:lang="ru">Siddiqui M.M., Rais-Bahrami S., Truong H., et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy // Eur Urol. 2013. Vol. 64, N 5. P. 713–719. doi: 10.1016/j.eururo.2013.05.059</mixed-citation><mixed-citation xml:lang="zh">Siddiqui MM, Rais-Bahrami S, Truong H, et al. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013;64(5):713–719. doi: 10.1016/j.eururo.2013.05.059</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Bjurlin MA, Meng X, Le Nobin J, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014;192(3):648–658. doi: 10.1016/j.juro.2014.03.117</mixed-citation><mixed-citation xml:lang="ru">Bjurlin M.A., Meng X., Le Nobin J., et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment // J Urol. 2014. Vol. 192, N 3. P. 648–658. doi: 10.1016/j.juro.2014.03.117</mixed-citation><mixed-citation xml:lang="zh">Bjurlin MA, Meng X, Le Nobin J, et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. J Urol. 2014;192(3):648–658. doi: 10.1016/j.juro.2014.03.117</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">[WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK: Public Health England; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks</mixed-citation><mixed-citation xml:lang="ru">[WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK : Public Health England, 2016. Доступ по ссылке: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks</mixed-citation><mixed-citation xml:lang="zh">[WITHDRAWN] Prostate cancer risk management programme (PCRMP): benefits and risks of PSA testing (guidance) [Internet]. UK: Public Health England; 2016. Available from: https://www.gov.uk/government/publications/prostate-cancer-risk-management-programme-psa-test-benefits-and-risks</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol. 2015;67(6):1112–1121. doi: 10.1016/j.eururo.2014.10.033</mixed-citation><mixed-citation xml:lang="ru">Hamoen E.H.J., de Rooij M., Witjes J.A., Barentsz J.O., Rovers M.M. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis // Eur Urol. 2015. Vol. 67, N 6. P. 1112–1121. doi: 10.1016/j.eururo.2014.10.033</mixed-citation><mixed-citation xml:lang="zh">Hamoen EHJ, de Rooij M, Witjes JA, Barentsz JO, Rovers MM. Use of the Prostate Imaging Reporting and Data System (PI-RADS) for Prostate Cancer Detection with Multiparametric Magnetic Resonance Imaging: A Diagnostic Meta-analysis. Eur Urol. 2015;67(6):1112–1121. doi: 10.1016/j.eururo.2014.10.033</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Ventrella E, Eusebi L, Carpagnano FA, et al. Multiparametric MRI of Prostate Cancer: Recent Advances. Curr Radiol Rep. 2020;8. doi: 10.1007/s40134-020-00363-1</mixed-citation><mixed-citation xml:lang="ru">Ventrella E., Eusebi L., Carpagnano F.A., et al. Multiparametric MRI of Prostate Cancer: Recent Advances // Curr Radiol Rep. 2020. Vol. 8. doi: 10.1007/s40134-020-00363-1</mixed-citation><mixed-citation xml:lang="zh">Ventrella E, Eusebi L, Carpagnano FA, et al. Multiparametric MRI of Prostate Cancer: Recent Advances. Curr Radiol Rep. 2020;8. doi: 10.1007/s40134-020-00363-1</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol. 2012;62(6):986–996. doi: 10.1016/j.eururo.2012.06.044</mixed-citation><mixed-citation xml:lang="ru">Portalez D., Mozer P., Cornud F., et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients // Eur Urol. 2012. Vol. 62, N 6. P. 986–996. doi: 10.1016/j.eururo.2012.06.044</mixed-citation><mixed-citation xml:lang="zh">Portalez D, Mozer P, Cornud F, et al. Validation of the European Society of Urogenital Radiology scoring system for prostate cancer diagnosis on multiparametric magnetic resonance imaging in a cohort of repeat biopsy patients. Eur Urol. 2012;62(6):986–996. doi: 10.1016/j.eururo.2012.06.044</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Kuru TH, Roethke MC, Rieker P, et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int. 2013;112(8):1080–1087. doi: 10.1111/bju.12259</mixed-citation><mixed-citation xml:lang="ru">Kuru T.H., Roethke M.C., Rieker P., et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate // BJU Int. 2013. Vol. 112, N 8. P. 1080–1087. doi: 10.1111/bju.12259</mixed-citation><mixed-citation xml:lang="zh">Kuru TH, Roethke MC, Rieker P, et al. Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate. BJU Int. 2013;112(8):1080–1087. doi: 10.1111/bju.12259</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Carpagnano F, Eusebi L, Tupputi U, et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020;8. doi: 10.1007/s40134-020-00374-y</mixed-citation><mixed-citation xml:lang="ru">Carpagnano F., Eusebi L., Tupputi U., et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020. Vol. 8. doi: 10.1007/s40134-020-00374-y</mixed-citation><mixed-citation xml:lang="zh">Carpagnano F, Eusebi L, Tupputi U, et al. Multiparametric MRI: Local Staging of Prostate Cancer. Current Radiology Reports. 2020;8. doi: 10.1007/s40134-020-00374-y</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Arsov C, Rabenalt R, Blondin D, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68(4):713–720. doi: 10.1016/j.eururo.2015.06.008</mixed-citation><mixed-citation xml:lang="ru">Arsov C., Rabenalt R., Blondin D., et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies // Eur Urol. 2015. Vol. 68, N 4. P. 713–720. doi: 10.1016/j.eururo.2015.06.008</mixed-citation><mixed-citation xml:lang="zh">Arsov C, Rabenalt R, Blondin D, et al. Prospective randomized trial comparing magnetic resonance imaging (MRI)-guided in-bore biopsy to MRI-ultrasound fusion and transrectal ultrasound-guided prostate biopsy in patients with prior negative biopsies. Eur Urol. 2015;68(4):713–720. doi: 10.1016/j.eururo.2015.06.008</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183(2):520–527. doi: 10.1016/j.juro.2009.10.022</mixed-citation><mixed-citation xml:lang="ru">Hambrock T., Somford D.M., Hoeks C., et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen // J Urol. 2010. Vol. 183, N 2. P. 520–527. doi: 10.1016/j.juro.2009.10.022</mixed-citation><mixed-citation xml:lang="zh">Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010;183(2):520–527. doi: 10.1016/j.juro.2009.10.022</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Tyson MD, Arora SS, Scarpato KR, Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol. 2016;34(7):326–332. doi: 10.1016/j.urolonc.2016.03.005</mixed-citation><mixed-citation xml:lang="ru">Tyson M.D., Arora S.S., Scarpato K.R., Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer // Urol Oncol. 2016. Vol. 34, N 7. P. 326–332. doi: 10.1016/j.urolonc.2016.03.005</mixed-citation><mixed-citation xml:lang="zh">Tyson MD, Arora SS, Scarpato KR, Barocas D. Magnetic resonance-ultrasound fusion prostate biopsy in the diagnosis of prostate cancer. Urol Oncol. 2016;34(7):326–332. doi: 10.1016/j.urolonc.2016.03.005</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Wolters T, Montironi R, Mazzucchelli R, et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate. 2012;72(1):108–115. doi: 10.1002/pros.21415</mixed-citation><mixed-citation xml:lang="ru">Wolters T., Montironi R., Mazzucchelli R., et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy // Prostate. 2012. Vol. 72, N 1. P. 108–115. doi: 10.1002/pros.21415</mixed-citation><mixed-citation xml:lang="zh">Wolters T, Montironi R, Mazzucchelli R, et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate. 2012;72(1):108–115. doi: 10.1002/pros.21415</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–140. doi: 10.1016/j.eururo.2012.06.004</mixed-citation><mixed-citation xml:lang="ru">Moore C.M., Robertson N.L., Arsanious N., et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review // Eur Urol. 2013. Vol. 63, N 1. P. 125–140. doi: 10.1016/j.eururo.2012.06.004</mixed-citation><mixed-citation xml:lang="zh">Moore CM, Robertson NL, Arsanious N, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol. 2013;63(1):125–140. doi: 10.1016/j.eururo.2012.06.004</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study. Radiology. 2013;268(2):461–469. doi: 10.1148/radiol.13121501</mixed-citation><mixed-citation xml:lang="ru">Puech P., Rouvière O., Renard-Penna R., et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study // Radiology. 2013. Vol. 268, N 2. P. 461–469. doi: 10.1148/radiol.13121501</mixed-citation><mixed-citation xml:lang="zh">Puech P, Rouvière O, Renard-Penna R, et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy — prospective multicenter study. Radiology. 2013;268(2):461–469. doi: 10.1148/radiol.13121501</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis. 2010;13(1):65–70. doi: 10.1038/pcan.2009.41</mixed-citation><mixed-citation xml:lang="ru">Labanaris A.P., Engelhard K., Zugor V., Nützel R., Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate // Prostate Cancer Prostatic Dis. 2010. Vol. 13, N 1. P. 65–70. doi: 10.1038/pcan.2009.41</mixed-citation><mixed-citation xml:lang="zh">Labanaris AP, Engelhard K, Zugor V, Nützel R, Kühn R. Prostate cancer detection using an extended prostate biopsy schema in combination with additional targeted cores from suspicious images in conventional and functional endorectal magnetic resonance imaging of the prostate. Prostate Cancer Prostatic Dis. 2010;13(1):65–70. doi: 10.1038/pcan.2009.41</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;217(8):424–433. doi: 10.5694/mja2.51722</mixed-citation><mixed-citation xml:lang="ru">Williams I.S., McVey A., Perera S., et al. Modern paradigms for prostate cancer detection and management // Med J Aust. 2022. Vol. 217, N 8. P. 424–433. doi: 10.5694/mja2.51722</mixed-citation><mixed-citation xml:lang="zh">Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management. Med J Aust. 2022;217(8):424–433. doi: 10.5694/mja2.51722</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108(8 Pt 2):E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x</mixed-citation><mixed-citation xml:lang="ru">Haffner J., Lemaitre L., Puech P., et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection // BJU Int. 2011. Vol. 108, N 8 Pt 2. P. E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x</mixed-citation><mixed-citation xml:lang="zh">Haffner J, Lemaitre L, Puech P, et al. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int. 2011;108(8 Pt 2):E171–E178. doi: 10.1111/j.1464-410X.2011.10112.x</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Labanaris AP, Zugor V, Smiszek R, et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology. Magn Reson Imaging. 2010;28(7):943–946. doi: 10.1016/j.mri.2010.03.041</mixed-citation><mixed-citation xml:lang="ru">Labanaris A.P., Zugor V., Smiszek R., et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology // Magn Reson Imaging. 2010. Vol. 28, N 7. P. 943–946. doi: 10.1016/j.mri.2010.03.041</mixed-citation><mixed-citation xml:lang="zh">Labanaris AP, Zugor V, Smiszek R, et al. Guided e-MRI prostate biopsy can solve the discordance between Gleason score biopsy and radical prostatectomy pathology. Magn Reson Imaging. 2010;28(7):943–946. doi: 10.1016/j.mri.2010.03.041</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am. 2014;41(2):315–326. doi: 10.1016/j.ucl.2014.01.007</mixed-citation><mixed-citation xml:lang="ru">Stephenson S.K., Chang E.K., Marks L.S. Screening and detection advances in magnetic resonance image-guided prostate biopsy // Urol Clin North Am. 2014. Vol. 41, N 2. P. 315–326. doi: 10.1016/j.ucl.2014.01.007</mixed-citation><mixed-citation xml:lang="zh">Stephenson SK, Chang EK, Marks LS. Screening and detection advances in magnetic resonance image-guided prostate biopsy. Urol Clin North Am. 2014;41(2):315–326. doi: 10.1016/j.ucl.2014.01.007</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Vourganti S, Rastinehad A, Yerram N, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188(6):2152–2157. doi: 10.1016/j.juro.2012.08.025</mixed-citation><mixed-citation xml:lang="ru">Vourganti S., Rastinehad A., Yerram N., et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies // J Urol. 2012. Vol. 188, N 6. P. 2152–2157. doi: 10.1016/j.juro.2012.08.025</mixed-citation><mixed-citation xml:lang="zh">Vourganti S, Rastinehad A, Yerram N, et al. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012;188(6):2152–2157. doi: 10.1016/j.juro.2012.08.025</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–397. doi: 10.1001/jama.2014.17942</mixed-citation><mixed-citation xml:lang="ru">Siddiqui M.M., Rais-Bahrami S., Turkbey B., et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer // JAMA. 2015. Vol. 313, N 4. P. 390–397. doi: 10.1001/jama.2014.17942</mixed-citation><mixed-citation xml:lang="zh">Siddiqui MM, Rais-Bahrami S, Turkbey B, et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. JAMA. 2015;313(4):390–397. doi: 10.1001/jama.2014.17942</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Quentin M, Schimmöller L, Arsov C, et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. Acta Radiol. 2013;54(10):1224–1229. doi: 10.1177/0284185113492972</mixed-citation><mixed-citation xml:lang="ru">Quentin M., Schimmöller L., Arsov C., et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization // Acta Radiol. 2013. Vol. 54, N 10. P. 1224–1229. doi: 10.1177/0284185113492972</mixed-citation><mixed-citation xml:lang="zh">Quentin M, Schimmöller L, Arsov C, et al. 3-T in-bore MR-guided prostate biopsy based on a scoring system for target lesions characterization. Acta Radiol. 2013;54(10):1224–1229. doi: 10.1177/0284185113492972</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902–909. doi: 10.1016/j.eururo.2012.01.047</mixed-citation><mixed-citation xml:lang="ru">Hoeks C.M., Schouten M.G., Bomers J.G., et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers // Eur Urol. 2012. Vol. 62, N 5. P. 902–909. doi: 10.1016/j.eururo.2012.01.047</mixed-citation><mixed-citation xml:lang="zh">Hoeks CM, Schouten MG, Bomers JG, et al. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012;62(5):902–909. doi: 10.1016/j.eururo.2012.01.047</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013;23(1):43–50. doi: 10.1097/MOU.0b013e32835ad3ee</mixed-citation><mixed-citation xml:lang="ru">Marks L., Young S., Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy // Curr Opin Urol. 2013. Vol. 23, N 1. P. 43–50. doi: 10.1097/MOU.0b013e32835ad3ee</mixed-citation><mixed-citation xml:lang="zh">Marks L, Young S, Natarajan S. MRI-ultrasound fusion for guidance of targeted prostate biopsy. Curr Opin Urol. 2013;23(1):43–50. doi: 10.1097/MOU.0b013e32835ad3ee</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Monni F, Fontanella P, Grasso A, et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review. Minerva Urol Nefrol. 2017;69(6):567–578. doi: 10.23736/S0393-2249.17.02819-3</mixed-citation><mixed-citation xml:lang="ru">Monni F., Fontanella P., Grasso A., et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review // Minerva Urol Nefrol. 2017. Vol. 69, N 6. P. 567–578. doi: 10.23736/S0393-2249.17.02819-3</mixed-citation><mixed-citation xml:lang="zh">Monni F, Fontanella P, Grasso A, et al. Magnetic resonance imaging in prostate cancer detection and management: a systematic review. Minerva Urol Nefrol. 2017;69(6):567–578. doi: 10.23736/S0393-2249.17.02819-3</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Schlaier JR, Warnat J, Dorenbeck U, et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system. Acta Neurochir (Wien). 2004;146(3):271–276. doi: 10.1007/s00701-003-0155-6</mixed-citation><mixed-citation xml:lang="ru">Schlaier J.R., Warnat J., Dorenbeck U., et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system // Acta Neurochir (Wien). 2004. Vol. 146, N 3. P. 271–276. doi: 10.1007/s00701-003-0155-6</mixed-citation><mixed-citation xml:lang="zh">Schlaier JR, Warnat J, Dorenbeck U, et al. Image fusion of MR images and real-time ultrasonography: evaluation of fusion accuracy combining two commercial instruments, a neuronavigation system and a ultrasound system. Acta Neurochir (Wien). 2004;146(3):271–276. doi: 10.1007/s00701-003-0155-6</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66(1):22–29. doi: 10.1016/j.eururo.2014.03.002</mixed-citation><mixed-citation xml:lang="ru">Pokorny M.R., de Rooij M., Duncan E., et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies // Eur Urol. 2014. Vol. 66, N 1. P. 22–29. doi: 10.1016/j.eururo.2014.03.002</mixed-citation><mixed-citation xml:lang="zh">Pokorny MR, de Rooij M, Duncan E, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol. 2014;66(1):22–29. doi: 10.1016/j.eururo.2014.03.002</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol. 2013;190(4):1380–1386. doi: 10.1016/j.juro.2013.04.043</mixed-citation><mixed-citation xml:lang="ru">Kuru T.H., Roethke M.C., Seidenader J., et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer // J Urol. 2013. Vol. 190, N 4. P. 1380–1386. doi: 10.1016/j.juro.2013.04.043</mixed-citation><mixed-citation xml:lang="zh">Kuru TH, Roethke MC, Seidenader J, et al. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer. J Urol. 2013;190(4):1380–1386. doi: 10.1016/j.juro.2013.04.043</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Serefoglu EC, Altinova S, Ugras NS, et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer. Can Urol Assoc J. 2013;7(5-6):E293–E298. doi: 10.5489/cuaj.11224</mixed-citation><mixed-citation xml:lang="ru">Serefoglu E.C., Altinova S., Ugras N.S., et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer? // Can Urol Assoc J. 2013. Vol. 7, N 5-6. P. E293–E298. doi: 10.5489/cuaj.11224</mixed-citation><mixed-citation xml:lang="zh">Serefoglu EC, Altinova S, Ugras NS, et al. How reliable is 12-core prostate biopsy procedure in the detection of prostate cancer. Can Urol Assoc J. 2013;7(5-6):E293–E298. doi: 10.5489/cuaj.11224</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Baco E, Ukimura O, Rud E, et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. 2015;67(4):787–794. doi: 10.1016/j.eururo.2014.08.077</mixed-citation><mixed-citation xml:lang="ru">Baco E., Ukimura O., Rud E., et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients // Eur Urol. 2015. Vol. 67, N 4. P. 787–794. doi: 10.1016/j.eururo.2014.08.077</mixed-citation><mixed-citation xml:lang="zh">Baco E, Ukimura O, Rud E, et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol. 2015;67(4):787–794. doi: 10.1016/j.eururo.2014.08.077</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Cerantola Y, Dragomir A, Tanguay S, et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. Urol Oncol. 2016;34(3):119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010</mixed-citation><mixed-citation xml:lang="ru">Cerantola Y., Dragomir A., Tanguay S., et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer // Urol Oncol. 2016. Vol. 34, N 3. P. 119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010</mixed-citation><mixed-citation xml:lang="zh">Cerantola Y, Dragomir A, Tanguay S, et al. Cost-effectiveness of multiparametric magnetic resonance imaging and targeted biopsy in diagnosing prostate cancer. Urol Oncol. 2016;34(3):119.e1–119.e9. doi: 10.1016/j.urolonc.2015.09.010</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol. 2013;189(2):493–499. doi: 10.1016/j.juro.2012.08.195</mixed-citation><mixed-citation xml:lang="ru">Delongchamps N.B., Peyromaure M., Schull A., et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies // J Urol. 2013. Vol. 189, N 2. P. 493–499. doi: 10.1016/j.juro.2012.08.195</mixed-citation><mixed-citation xml:lang="zh">Delongchamps NB, Peyromaure M, Schull A, et al. Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies. J Urol. 2013;189(2):493–499. doi: 10.1016/j.juro.2012.08.195</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Bax J, Cool D, Gardi L, et al. Mechanically assisted 3D ultrasound guided prostate biopsy system. Med Phys. 2008;35(12):5397–5410. doi: 10.1118/1.3002415</mixed-citation><mixed-citation xml:lang="ru">Bax J., Cool D., Gardi L., et al. Mechanically assisted 3D ultrasound guided prostate biopsy system // Med Phys. 2008. Vol. 35, N 12. P. 5397–5410. doi: 10.1118/1.3002415</mixed-citation><mixed-citation xml:lang="zh">Bax J, Cool D, Gardi L, et al. Mechanically assisted 3D ultrasound guided prostate biopsy system. Med Phys. 2008;35(12):5397–5410. doi: 10.1118/1.3002415</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913. Erratum in: JAMA. 2018;319(23):2443. doi: 10.1001/jama.2018.3710</mixed-citation><mixed-citation xml:lang="ru">US Preventive Services Task Force; Grossman D.C., Curry S.J., et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement // JAMA. 2018. Vol. 319, N 18. P. 1901–1913. Erratum in: JAMA. 2018. Vol. 319, N 23. P. 2443. doi: 10.1001/jama.2018.3710</mixed-citation><mixed-citation xml:lang="zh">US Preventive Services Task Force; Grossman DC, Curry SJ, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;319(18):1901–1913. Erratum in: JAMA. 2018;319(23):2443. doi: 10.1001/jama.2018.3710</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354–360. doi: 10.1016/j.eururo.2014.12.006</mixed-citation><mixed-citation xml:lang="ru">Arnsrud Godtman R., Holmberg E., Lilja H., Stranne J., Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial // Eur Urol. 2015. Vol. 68, N 3. P. 354–360. doi: 10.1016/j.eururo.2014.12.006</mixed-citation><mixed-citation xml:lang="zh">Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354–360. doi: 10.1016/j.eururo.2014.12.006</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Engler J, Dahlhaus A, Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey. Eur J Gen Pract. 2017;23(1):11–19. doi: 10.1080/13814788.2016.1240166</mixed-citation><mixed-citation xml:lang="ru">Engler J., Dahlhaus A., Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey // Eur J Gen Pract. 2017. Vol. 23, N 1. P. 11–19. doi: 10.1080/13814788.2016.1240166</mixed-citation><mixed-citation xml:lang="zh">Engler J, Dahlhaus A, Güthlin C. The readiness of German GPs to recommend and conduct cancer screening is associated with patient-physician gender concordance. Results of a survey. Eur J Gen Pract. 2017;23(1):11–19. doi: 10.1080/13814788.2016.1240166</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Nordström T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–425. doi: 10.1016/j.eururo.2012.10.001</mixed-citation><mixed-citation xml:lang="ru">Nordström T., Aly M., Clements M.S., et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011 // Eur Urol. 2013. Vol. 63, N 3. P. 419–425. doi: 10.1016/j.eururo.2012.10.001</mixed-citation><mixed-citation xml:lang="zh">Nordström T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419–425. doi: 10.1016/j.eururo.2012.10.001</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021;80(6):703–711. doi: 10.1016/j.eururo.2021.07.024</mixed-citation><mixed-citation xml:lang="ru">Van Poppel H., Roobol M.J., Chapple C.R., et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021 // Eur Urol. 2021. Vol. 80, N 6. P. 703–711. doi: 10.1016/j.eururo.2021.07.024</mixed-citation><mixed-citation xml:lang="zh">Van Poppel H, Roobol MJ, Chapple CR, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. Eur Urol. 2021;80(6):703–711. doi: 10.1016/j.eururo.2021.07.024</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042</mixed-citation><mixed-citation xml:lang="ru">Mottet N., van den Bergh R.C.N., Briers E., et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent // Eur Urol. 2021. Vol. 79, N 2. P. 243–262. doi: 10.1016/j.eururo.2020.09.042</mixed-citation><mixed-citation xml:lang="zh">Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–262. doi: 10.1016/j.eururo.2020.09.042</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Collen S, Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe. Belg J Med Oncol. 2020;14:321–326.</mixed-citation><mixed-citation xml:lang="ru">Collen S., Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe // Belg J Med Oncol. 2020. Vol. 14. P. 321–326.</mixed-citation><mixed-citation xml:lang="zh">Collen S, Van Poppel H. Early detection and diagnosis of prostate cancer in well informed men: the way forward for Europe. Belg J Med Oncol. 2020;14:321–326.</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26(5):848–864. doi: 10.1093/annonc/mdu525</mixed-citation><mixed-citation xml:lang="ru">Louie K.S., Seigneurin A., Cathcart P., Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis // Ann Oncol. 2015. Vol. 26, N 5. P. 848–864. doi: 10.1093/annonc/mdu525</mixed-citation><mixed-citation xml:lang="zh">Louie KS, Seigneurin A, Cathcart P, Sasieni P. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Ann Oncol. 2015;26(5):848–864. doi: 10.1093/annonc/mdu525</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi: 10.1016/S0140-6736(16)32401-1</mixed-citation><mixed-citation xml:lang="ru">Ahmed H.U., El-Shater Bosaily A., Brown L.C., et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study // Lancet. 2017. Vol. 389, N 10071. P. 815–822. doi: 10.1016/S0140-6736(16)32401-1</mixed-citation><mixed-citation xml:lang="zh">Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi: 10.1016/S0140-6736(16)32401-1</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Alberts AR, Schoots IG, Bokhorst LP, et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging. Eur Urol. 2018;73(3):343–350. doi: 10.1016/j.eururo.2017.06.019</mixed-citation><mixed-citation xml:lang="ru">Alberts A.R., Schoots I.G., Bokhorst L.P., et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging? // Eur Urol. 2018. Vol. 73, N 3. P. 343–350. doi: 10.1016/j.eururo.2017.06.019</mixed-citation><mixed-citation xml:lang="zh">Alberts AR, Schoots IG, Bokhorst LP, et al. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging. Eur Urol. 2018;73(3):343–350. doi: 10.1016/j.eururo.2017.06.019</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Palsdottir T, Nordstrom T, Karlsson A, et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. BMJ Open. 2019;9(3):e027958. doi: 10.1136/bmjopen-2018-027958</mixed-citation><mixed-citation xml:lang="ru">Palsdottir T., Nordstrom T., Karlsson A., et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study // BMJ Open. 2019. Vol. 9, N 3. P. e027958. doi: 10.1136/bmjopen-2018-027958</mixed-citation><mixed-citation xml:lang="zh">Palsdottir T, Nordstrom T, Karlsson A, et al. The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study. BMJ Open. 2019;9(3):e027958. doi: 10.1136/bmjopen-2018-027958</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Wynants L, van Smeden M, McLernon DJ, et al. Three myths about risk thresholds for prediction models. BMC Med. 2019;17(1):192. doi: 10.1186/s12916-019-1425-3</mixed-citation><mixed-citation xml:lang="ru">Wynants L., van Smeden M., McLernon D.J., et al. Three myths about risk thresholds for prediction models // BMC Med. 2019. Vol. 17, N 1. P. 192. doi: 10.1186/s12916-019-1425-3</mixed-citation><mixed-citation xml:lang="zh">Wynants L, van Smeden M, McLernon DJ, et al. Three myths about risk thresholds for prediction models. BMC Med. 2019;17(1):192. doi: 10.1186/s12916-019-1425-3</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><citation-alternatives><mixed-citation xml:lang="en">Sonn GA, Margolis DJ, Marks LS. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014;32(6):903–911. doi: 10.1016/j.urolonc.2013.08.006</mixed-citation><mixed-citation xml:lang="ru">Sonn G.A., Margolis D.J., Marks L.S. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy // Urol Oncol. 2014. Vol. 32, N 6. P. 903–911. doi: 10.1016/j.urolonc.2013.08.006</mixed-citation><mixed-citation xml:lang="zh">Sonn GA, Margolis DJ, Marks LS. Target detection: magnetic resonance imaging-ultrasound fusion-guided prostate biopsy. Urol Oncol. 2014;32(6):903–911. doi: 10.1016/j.urolonc.2013.08.006</mixed-citation></citation-alternatives></ref><ref id="B48"><label>48.</label><citation-alternatives><mixed-citation xml:lang="en">Sonn GA, Natarajan S, Margolis DJ, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013;189(1):86–91. doi: 10.1016/j.juro.2012.08.095</mixed-citation><mixed-citation xml:lang="ru">Sonn G.A., Natarajan S., Margolis D.J., et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device // J Urol. 2013. Vol. 189, N 1. P. 86–91. doi: 10.1016/j.juro.2012.08.095</mixed-citation><mixed-citation xml:lang="zh">Sonn GA, Natarajan S, Margolis DJ, et al. Targeted biopsy in the detection of prostate cancer using an office based magnetic resonance ultrasound fusion device. J Urol. 2013;189(1):86–91. doi: 10.1016/j.juro.2012.08.095</mixed-citation></citation-alternatives></ref><ref id="B49"><label>49.</label><citation-alternatives><mixed-citation xml:lang="en">Robertson NL, Hu Y, Ahmed HU, et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study. Eur Urol. 2014;65(3):628–634. doi: 10.1016/j.eururo.2012.12.057</mixed-citation><mixed-citation xml:lang="ru">Robertson N.L., Hu Y., Ahmed H.U., et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study // Eur Urol. 2014. Vol. 65, N 3. P. 628–634. doi: 10.1016/j.eururo.2012.12.057</mixed-citation><mixed-citation xml:lang="zh">Robertson NL, Hu Y, Ahmed HU, et al. Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study. Eur Urol. 2014;65(3):628–634. doi: 10.1016/j.eururo.2012.12.057</mixed-citation></citation-alternatives></ref><ref id="B50"><label>50.</label><citation-alternatives><mixed-citation xml:lang="en">Radtke JP, Schwab C, Wolf MB, et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846–853. doi: 10.1016/j.eururo.2015.12.052</mixed-citation><mixed-citation xml:lang="ru">Radtke J.P., Schwab C., Wolf M.B., et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen // Eur Urol. 2016. Vol. 70. P. 846–853. doi: 10.1016/j.eururo.2015.12.052</mixed-citation><mixed-citation xml:lang="zh">Radtke JP, Schwab C, Wolf MB, et al. Multiparametric magnetic resonance imaging (MRI) and MRI — transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen. Eur Urol. 2016;70:846–853. doi: 10.1016/j.eururo.2015.12.052</mixed-citation></citation-alternatives></ref><ref id="B51"><label>51.</label><citation-alternatives><mixed-citation xml:lang="en">Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi: 10.1016/S0140-6736(14)60525-0</mixed-citation><mixed-citation xml:lang="ru">Schröder F.H., Hugosson J., Roobol M.J., et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up // Lancet. 2014. Vol. 384, N 9959. P. 2027–2035. doi: 10.1016/S0140-6736(14)60525-0</mixed-citation><mixed-citation xml:lang="zh">Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035. doi: 10.1016/S0140-6736(14)60525-0</mixed-citation></citation-alternatives></ref><ref id="B52"><label>52.</label><citation-alternatives><mixed-citation xml:lang="en">Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85. doi: 10.1016/j.eururo.2009.08.025</mixed-citation><mixed-citation xml:lang="ru">Roobol M.J., Steyerberg E.W., Kranse R., et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer // Eur Urol. 2010. Vol. 57, N 1. P. 79–85. doi: 10.1016/j.eururo.2009.08.025</mixed-citation><mixed-citation xml:lang="zh">Roobol MJ, Steyerberg EW, Kranse R, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol. 2010;57(1):79–85. doi: 10.1016/j.eururo.2009.08.025</mixed-citation></citation-alternatives></ref><ref id="B53"><label>53.</label><citation-alternatives><mixed-citation xml:lang="en">Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69(3):512–517. doi: 10.1016/j.eururo.2015.06.005</mixed-citation><mixed-citation xml:lang="ru">Meng X., Rosenkrantz A.B., Mendhiratta N., et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes // Eur Urol. 2016. Vol. 69, N 3. P. 512–517. doi: 10.1016/j.eururo.2015.06.005</mixed-citation><mixed-citation xml:lang="zh">Meng X, Rosenkrantz AB, Mendhiratta N, et al. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes. Eur Urol. 2016;69(3):512–517. doi: 10.1016/j.eururo.2015.06.005</mixed-citation></citation-alternatives></ref><ref id="B54"><label>54.</label><citation-alternatives><mixed-citation xml:lang="en">Vargas HA, Hötker AM, Goldman DA, et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol. 2016;26(6):1606–1612. doi: 10.1007/s00330-015-4015-6</mixed-citation><mixed-citation xml:lang="ru">Vargas H.A., Hötker A.M., Goldman D.A., et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference // Eur Radiol. 2016. Vol. 26, N 6. P. 1606–1612. doi: 10.1007/s00330-015-4015-6</mixed-citation><mixed-citation xml:lang="zh">Vargas HA, Hötker AM, Goldman DA, et al. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. Eur Radiol. 2016;26(6):1606–1612. doi: 10.1007/s00330-015-4015-6</mixed-citation></citation-alternatives></ref><ref id="B55"><label>55.</label><citation-alternatives><mixed-citation xml:lang="en">Radtke JP, Wiesenfarth M, Kesch C, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. 2017;72(6):888–896. doi: 10.1016/j.eururo.2017.03.039</mixed-citation><mixed-citation xml:lang="ru">Radtke J.P., Wiesenfarth M., Kesch C., et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies // Eur Urol. 2017. Vol. 72, N 6. P. 888–896. doi: 10.1016/j.eururo.2017.03.039</mixed-citation><mixed-citation xml:lang="zh">Radtke JP, Wiesenfarth M, Kesch C, et al. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Eur Urol. 2017;72(6):888–896. doi: 10.1016/j.eururo.2017.03.039</mixed-citation></citation-alternatives></ref><ref id="B56"><label>56.</label><citation-alternatives><mixed-citation xml:lang="en">van Leeuwen PJ, Hayen A, Thompson JE, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017;120(6):774–781. doi: 10.1111/bju.13814</mixed-citation><mixed-citation xml:lang="ru">van Leeuwen P.J., Hayen A., Thompson J.E., et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy // BJU Int. 2017. Vol. 120, N 6. P. 774–781. doi: 10.1111/bju.13814</mixed-citation><mixed-citation xml:lang="zh">van Leeuwen PJ, Hayen A, Thompson JE, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017;120(6):774–781. doi: 10.1111/bju.13814</mixed-citation></citation-alternatives></ref><ref id="B57"><label>57.</label><citation-alternatives><mixed-citation xml:lang="en">Muthigi A, George AK, Sidana A, et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. J Urol. 2017;197(2):327–334. doi: 10.1016/j.juro.2016.08.097</mixed-citation><mixed-citation xml:lang="ru">Muthigi A., George A.K., Sidana A., et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy // J Urol. 2017. Vol. 197, N 2. P. 327–334. doi: 10.1016/j.juro.2016.08.097</mixed-citation><mixed-citation xml:lang="zh">Muthigi A, George AK, Sidana A, et al. Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. J Urol. 2017;197(2):327–334. doi: 10.1016/j.juro.2016.08.097</mixed-citation></citation-alternatives></ref><ref id="B58"><label>58.</label><citation-alternatives><mixed-citation xml:lang="en">Cash H, Günzel K, Maxeiner A, et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int. 2016;118(1):35–43. doi: 10.1111/bju.13327</mixed-citation><mixed-citation xml:lang="ru">Cash H., Günzel K., Maxeiner A., et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure // BJU Int. 2016. Vol. 118, N 1. P. 35–43. doi: 10.1111/bju.13327</mixed-citation><mixed-citation xml:lang="zh">Cash H, Günzel K, Maxeiner A, et al. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure. BJU Int. 2016;118(1):35–43. doi: 10.1111/bju.13327</mixed-citation></citation-alternatives></ref><ref id="B59"><label>59.</label><citation-alternatives><mixed-citation xml:lang="en">Bryk DJ, Llukani E, Taneja SS, et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology. 2017;102:178–182. doi: 10.1016/j.urology.2016.11.017</mixed-citation><mixed-citation xml:lang="ru">Bryk D.J., Llukani E., Taneja S.S., et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy // Urology. 2017. Vol. 102. P. 178–182. doi: 10.1016/j.urology.2016.11.017</mixed-citation><mixed-citation xml:lang="zh">Bryk DJ, Llukani E, Taneja SS, et al. The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology. 2017;102:178–182. doi: 10.1016/j.urology.2016.11.017</mixed-citation></citation-alternatives></ref><ref id="B60"><label>60.</label><citation-alternatives><mixed-citation xml:lang="en">Porpiglia F, De Luca S, Passera R, et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization. J Urol. 2017;198(1):58–64. doi: 10.1016/j.juro.2017.01.036</mixed-citation><mixed-citation xml:lang="ru">Porpiglia F., De Luca S., Passera R., et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization // J Urol. 2017. Vol. 198, N 1. P. 58–64. doi: 10.1016/j.juro.2017.01.036</mixed-citation><mixed-citation xml:lang="zh">Porpiglia F, De Luca S, Passera R, et al. Multiparametric Magnetic Resonance/Ultrasound Fusion Prostate Biopsy: Number and Spatial Distribution of Cores for Better Index Tumor Detection and Characterization. J Urol. 2017;198(1):58–64. doi: 10.1016/j.juro.2017.01.036</mixed-citation></citation-alternatives></ref><ref id="B61"><label>61.</label><citation-alternatives><mixed-citation xml:lang="en">Fütterer JJ, Briganti A, De Visschere P, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015;68(6):1045–1053. doi: 10.1016/j.eururo.2015.01.013</mixed-citation><mixed-citation xml:lang="ru">Fütterer J.J., Briganti A., De Visschere P., et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature // Eur Urol. 2015. Vol. 68, N 6. P. 1045–1053. doi: 10.1016/j.eururo.2015.01.013</mixed-citation><mixed-citation xml:lang="zh">Fütterer JJ, Briganti A, De Visschere P, et al. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. Eur Urol. 2015;68(6):1045–1053. doi: 10.1016/j.eururo.2015.01.013</mixed-citation></citation-alternatives></ref><ref id="B62"><label>62.</label><citation-alternatives><mixed-citation xml:lang="en">Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol. 2014;192(1):67–74. doi: 10.1016/j.juro.2014.01.014</mixed-citation><mixed-citation xml:lang="ru">Thompson J.E., Moses D., Shnier R., et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study // J Urol. 2014. Vol. 192, N 1. P. 67–74. doi: 10.1016/j.juro.2014.01.014</mixed-citation><mixed-citation xml:lang="zh">Thompson JE, Moses D, Shnier R, et al. Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study. J Urol. 2014;192(1):67–74. doi: 10.1016/j.juro.2014.01.014</mixed-citation></citation-alternatives></ref><ref id="B63"><label>63.</label><citation-alternatives><mixed-citation xml:lang="en">Delongchamps NB, Portalez D, Bruguière E, et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer. J Urol. 2016;196(4):1069–1075. doi: 10.1016/j.juro.2016.04.003</mixed-citation><mixed-citation xml:lang="ru">Delongchamps N.B., Portalez D., Bruguière E., et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer? // J Urol. 2016. Vol. 196, N 4. P. 1069–1075. doi: 10.1016/j.juro.2016.04.003</mixed-citation><mixed-citation xml:lang="zh">Delongchamps NB, Portalez D, Bruguière E, et al. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer. J Urol. 2016;196(4):1069–1075. doi: 10.1016/j.juro.2016.04.003</mixed-citation></citation-alternatives></ref><ref id="B64"><label>64.</label><citation-alternatives><mixed-citation xml:lang="en">Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122(6):884–892. doi: 10.1002/cncr.29874</mixed-citation><mixed-citation xml:lang="ru">Filson C.P., Natarajan S., Margolis D.J., et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies // Cancer. 2016. Vol. 122, N 6. P. 884–892. doi: 10.1002/cncr.29874</mixed-citation><mixed-citation xml:lang="zh">Filson CP, Natarajan S, Margolis DJ, et al. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies. Cancer. 2016;122(6):884–892. doi: 10.1002/cncr.29874</mixed-citation></citation-alternatives></ref><ref id="B65"><label>65.</label><citation-alternatives><mixed-citation xml:lang="en">Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196(6):1613–1618. doi: 10.1016/j.juro.2016.06.079</mixed-citation><mixed-citation xml:lang="ru">Rosenkrantz A.B., Verma S., Choyke P., et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR // J Urol. 2016. Vol. 196, N 6. P. 1613–1618. doi: 10.1016/j.juro.2016.06.079</mixed-citation><mixed-citation xml:lang="zh">Rosenkrantz AB, Verma S, Choyke P, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016;196(6):1613–1618. doi: 10.1016/j.juro.2016.06.079</mixed-citation></citation-alternatives></ref><ref id="B66"><label>66.</label><citation-alternatives><mixed-citation xml:lang="en">Simmons LAM, Kanthabalan A, Arya M, et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer. 2017;116(9):1159–1165. doi: 10.1038/bjc.2017.57</mixed-citation><mixed-citation xml:lang="ru">Simmons L.A.M., Kanthabalan A., Arya M., et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy // Br J Cancer. 2017. Vol. 116, N 9. P. 1159–1165. doi: 10.1038/bjc.2017.57</mixed-citation><mixed-citation xml:lang="zh">Simmons LAM, Kanthabalan A, Arya M, et al. The PICTURE study: diagnostic accuracy of multiparametric MRI in men requiring a repeat prostate biopsy. Br J Cancer. 2017;116(9):1159–1165. doi: 10.1038/bjc.2017.57</mixed-citation></citation-alternatives></ref><ref id="B67"><label>67.</label><citation-alternatives><mixed-citation xml:lang="en">Hansen NL, Kesch C, Barrett T, et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017;120(5):631–638. doi: 10.1111/bju.13711</mixed-citation><mixed-citation xml:lang="ru">Hansen N.L., Kesch C., Barrett T., et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy // BJU Int. 2017. Vol. 120, N 5. P. 631–638. doi: 10.1111/bju.13711</mixed-citation><mixed-citation xml:lang="zh">Hansen NL, Kesch C, Barrett T, et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2017;120(5):631–638. doi: 10.1111/bju.13711</mixed-citation></citation-alternatives></ref><ref id="B68"><label>68.</label><citation-alternatives><mixed-citation xml:lang="en">Radtke JP, Kuru TH, Bonekamp D, et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis. 2016;19(3):283–291. doi: 10.1038/pcan.2016.16</mixed-citation><mixed-citation xml:lang="ru">Radtke J.P., Kuru T.H., Bonekamp D., et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance // Prostate Cancer Prostatic Dis. 2016. Vol. 19, N 3. P. 283–291. doi: 10.1038/pcan.2016.16</mixed-citation><mixed-citation xml:lang="zh">Radtke JP, Kuru TH, Bonekamp D, et al. Further reduction of disqualification rates by additional MRI-targeted biopsy with transperineal saturation biopsy compared with standard 12-core systematic biopsies for the selection of prostate cancer patients for active surveillance. Prostate Cancer Prostatic Dis. 2016;19(3):283–291. doi: 10.1038/pcan.2016.16</mixed-citation></citation-alternatives></ref><ref id="B69"><label>69.</label><citation-alternatives><mixed-citation xml:lang="en">Henderson DR, de Souza NM, Thomas K, et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. Eur Urol. 2016;69(6):1028–1033. doi: 10.1016/j.eururo.2015.10.010</mixed-citation><mixed-citation xml:lang="ru">Henderson D.R., de Souza N.M., Thomas K., et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort // Eur Urol. 2016. Vol. 69, N 6. P. 1028–1033. doi: 10.1016/j.eururo.2015.10.010</mixed-citation><mixed-citation xml:lang="zh">Henderson DR, de Souza NM, Thomas K, et al. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort. Eur Urol. 2016;69(6):1028–1033. doi: 10.1016/j.eururo.2015.10.010</mixed-citation></citation-alternatives></ref><ref id="B70"><label>70.</label><citation-alternatives><mixed-citation xml:lang="en">Frye TP, George AK, Kilchevsky A, et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. J Urol. 2017;197(3 Pt 1):640–646. doi: 10.1016/j.juro.2016.08.109</mixed-citation><mixed-citation xml:lang="ru">Frye T.P., George A.K., Kilchevsky A., et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer // J Urol. 2017. Vol. 197, N 3 Pt 1. P. 640–646. doi: 10.1016/j.juro.2016.08.109</mixed-citation><mixed-citation xml:lang="zh">Frye TP, George AK, Kilchevsky A, et al. Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. J Urol. 2017;197(3 Pt 1):640–646. doi: 10.1016/j.juro.2016.08.109</mixed-citation></citation-alternatives></ref><ref id="B71"><label>71.</label><citation-alternatives><mixed-citation xml:lang="en">Recabal P, Assel M, Sjoberg DD, et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. J Urol. 2016;196(2):374–381. doi: 10.1016/j.juro.2016.02.084</mixed-citation><mixed-citation xml:lang="ru">Recabal P., Assel M., Sjoberg D.D., et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance // J Urol. 2016. Vol. 196, N 2. P. 374–381. doi: 10.1016/j.juro.2016.02.084</mixed-citation><mixed-citation xml:lang="zh">Recabal P, Assel M, Sjoberg DD, et al. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance. J Urol. 2016;196(2):374–381. doi: 10.1016/j.juro.2016.02.084</mixed-citation></citation-alternatives></ref><ref id="B72"><label>72.</label><citation-alternatives><mixed-citation xml:lang="en">Tran GN, Leapman MS, Nguyen HG, et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017;72(2):275–281. doi: 10.1016/j.eururo.2016.08.023</mixed-citation><mixed-citation xml:lang="ru">Tran G.N., Leapman M.S., Nguyen H.G., et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance // Eur Urol. 2017. Vol. 72, N 2. P. 275–281. doi: 10.1016/j.eururo.2016.08.023</mixed-citation><mixed-citation xml:lang="zh">Tran GN, Leapman MS, Nguyen HG, et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017;72(2):275–281. doi: 10.1016/j.eururo.2016.08.023</mixed-citation></citation-alternatives></ref></ref-list></back></article>
